Cheryl Ward
Family · Sumter, SCNPI 1881764595
Payments from drug & device makers
Across 238 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$935
- Amgen$550
- Lilly USA, LLC$499
- Xeris Pharmaceuticals, Inc.$403
- Bayer$380
- Corcept Therapeutics$373
- plus $3K from 33 others
What the payments were for
- Travel & lodging$58210%
- Food & beverage$5,02289%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $935 |
| Amgen(2 entities) | 23 | $550 |
| Lilly USA, LLC | 26 | $499 |
| Xeris Pharmaceuticals, Inc. | 24 | $403 |
| Bayer | 16 | $380 |
| Corcept Therapeutics | 20 | $373 |
| Novo Nordisk | 10 | $334 |
| Abbott | 12 | $212 |
| AbbVie | 8 | $200 |
| Vifor Pharma, Inc. | 10 | $199 |
| Sanofi-aventis U.S. LLC | 9 | $178 |
| AstraZeneca(2 entities) | 10 | $167 |
| Renalytix AI, Inc. | 6 | $117 |
| Insulet Corporation | 5 | $115 |
| Madrigal Pharmaceuticals | 1 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $89 |
| Cequr Corporation | 3 | $87 |
| Boehringer Ingelheim | 4 | $76 |
| Intra-sana Laboratories | 2 | $69 |
| Johnson & Johnson | 4 | $61 |
| Esperion Therapeutics, Inc. | 2 | $54 |
| Ascensia Diabetes Care US Inc. | 2 | $46 |
| Mylan Specialty L.p. | 2 | $38 |
| Eisai Inc. | 2 | $38 |
| Pfizer | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $34 |
| Aurinia Pharma U.S., Inc. | 2 | $33 |
| Dexcom, Inc. | 2 | $30 |
| Medicure Pharma Inc. | 1 | $30 |
| Novartis | 2 | $27 |
| Verity Pharmaceuticals Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Integra Lifesciences Corporation | 1 | $22 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Organogenesis Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$577
- KRYSTEXXA$122
- Kerendia$117
- RYBELSUS$104
How this compares
$5,669 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 20 | $622,696 |
| OzempicSemaglutide | 416 | $560,725 |
| TrulicityDulaglutide | 244 | $303,651 |
| MounjaroTirzepatide | 171 | $218,389 |
| JardianceEmpagliflozin | 160 | $170,246 |
| FarxigaDapagliflozin Propanediol | 162 | $149,841 |
| Tresiba Flextouch U-200Insulin Degludec | 112 | $121,078 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 91 | $104,423 |
| Tresiba Flextouch U-100Insulin Degludec | 145 | $88,101 |
| JanuviaSitagliptin Phosphate | 51 | $57,750 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $57,011 |
| Humalog Kwikpen U-100Insulin Lispro | 216 | $53,271 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $53,219 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 37 | $43,647 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 311 | $41,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $373 | $622,69620 claims |
| Novo NordiskOzempic, Novolog | $334 | $565,279433 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Lyumjev | $499 | $543,681476 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $76 | $178,586172 claims |
| AstraZenecaFarxiga | $167 | $149,841162 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $178 | $14,95316 claims |
| AbbVieLinzess | $200 | $14,31213 claims |
| PfizerEliquis | $36 | $9,48916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.
Other family in Sumter
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.